alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › new-onset

new-onset

2 studies tagged new-onset, dated 2009-02-01 to 2021-10-21. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis 2021-10-21
  2. New-onset epilepsy risk factors in older veterans 2009-02-01

Studies

2 studies carry this tag.

Date range

2009 to 2021

Top journals

  • Frontiers in cardiovascular medicine 1
  • Journal of the American Geriatrics Society 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Frontiers in cardiovascular medicine 2021-10-21 Drug development

    A total of 13,276 SGLT2I and 36,544 DPP4I users (total n = 51,460; median age: 66.3 years old [interquartile range (IQR): 58-76], 55.65% men) were studied (follow-up: 472 [120-792] days).

  2. New-onset epilepsy risk factors in older veterans

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of the American Geriatrics Society 2009-02-01 Drug development

    These data suggest greater epilepsy risk for older individuals with CNS insult and an additive effect of cerebrovascular disease and dementia.

All topic tags with their study counts